Jesse Damsker Bio

Dr. Damsker has an extensive background in immunology and the regulation of inflammatory diseases. He earned his doctorate in immunology at the George Washington University School of Medicine and completed a post-doctoral fellowship at the National Institutes of Health. In 2010, Dr. Damsker brought his immunological expertise to ReveraGen and spearheaded studies that characterized vamorolone’s anti-inflammatory properties using in vitro and in vivo model systems of acute and chronic inflammation.

He subsequently transitioned to an operational role in which he was ReveraGen’s primary program manager of the vamorolone program, coordinating all non-clinical, clinical, regulatory, and supply chain efforts.   Based on his experience with ReveraGen, he co-founded HaliGene Therapeutics Inc. where he fulfills the role of Chief Operating Officer, acting as the primary HG-001 program manager, as well as, overseeing all business operations.